HIV阳性至HIV阳性肾移植受者抗逆转录病毒治疗方案回顾性分析
本回顾性研究纳入53例HIV阳性至HIV阳性肾移植受者,描述抗逆转录病毒治疗方案、换药原因及换药时机,并分析排斥反应与方案类型的关联。31例(58%)共发生46次换药,以方案性换药为主;维持基于蛋白酶抑制剂方案者排斥反应发生率较高(发生率比2.77,95%CI 1.03-7.48,P=0.044)。尽管换药频繁,多数受者HIV病毒载量保持抑制、移植物功能稳定。
要点
- 53例HIV阳性至HIV阳性肾移植受者中31例(58%)共发生46次抗逆转录病毒方案换药。
- 维持基于蛋白酶抑制剂方案与排斥反应存在关联(发生率比2.77,95%CI 1.03-7.48,P=0.044)。
- 尽管换药频繁,多数受者HIV病毒载量保持抑制、移植物功能稳定。
核心结论
- 尽管抗逆转录病毒方案换药频繁,本队列中多数HIV阳性肾移植受者HIV病毒载量保持抑制且移植物功能稳定。
- 维持基于蛋白酶抑制剂方案者排斥率升高信号值得关注。
研究设计与样本
- 回顾性综述,纳入53例HIV阳性至HIV阳性肾移植受者。
- 从移植日至研究终点(研究结束日期、死亡或移植物失败)描述抗逆转录病毒方案、换药原因及换药时机。
- 采用负二项回归分析排斥反应与抗逆转录病毒方案(基于蛋白酶抑制剂 vs 非基于蛋白酶抑制剂)的关联。
主要发现
- 53例中31例(58%)共发生46次换药。
- 方案性换药17/46次(37%),其中多数为从非核苷类逆转录酶抑制剂转换为蛋白酶抑制剂。
- 其他常见换药原因包括依非韦伦(EFV)诱导细胞色素P450酶(9/46,20%)、富马酸替诺福韦二吡呋酯(TDF)肾毒性(8/46,17%)或副作用(6/46,13%)。
- 46次换药中21次(46%)发生于移植住院期间,28次(62%)发生于移植后第一年。
- 维持基于蛋白酶抑制剂方案与排斥反应存在关联(发生率比2.77,95%CI 1.03-7.48,P=0.044)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The management of complex interactions between antiretroviral therapy (ART) and calcineurin inhibitor (CNI) immunosuppression regimens in HIV-positive to HIV-positive renal transplant recipients can be challenging. Literature describing ART regimens and indications for regimen switching in these patients is limited. METHODS: This retrospective review included 53 HIV-positive to HIV-positive renal transplant recipients. Data on ART regimens, reasons for ART switching, and timing of switches were described from day of transplant to study endpoint (end of study date, death, or graft failure). The association between rejection and ART regimen (protease inhibitor [PI] -based vs. non-PI-based regimen) was analyzed using negative binomial regression. RESULTS: There were a total of 46 switches in 31 of 53 patients (58%). Protocol switches (n = 17 of 46, 37%) accounted for most switches, of which the majority were from non-nucleoside reverse transcriptase inhibitors (NNRTIs) to PIs. Other common reasons for switching include cytochrome P450 enzyme induction from efavirenz (EFV) (9 of 46, 20%), tenofovir disoproxil fumarate (TDF) nephrotoxicity (8 of 46, 17%) or side effects (6 of 46, 13%). Of the 46 switches, nearly half (n = 21, 46%) occurred during the transplant admission period, and approximately two-thirds (n = 28, 62%) were during the first year post-transplantation. There was an association between rejection and being maintained on a PI-based regimen (incidence rate ratio 2.77 (95% confidence interval 1.03-7.48), P = 0.044). CONCLUSION: Despite frequent switching of ART regimens, HIV viral loads remained supressed and graft function remained stable in most HIV-positive kidney transplant recipients in our cohort. There was however a concerning signal for increased rejection rates in those on a PI-based regimen.
引用
- Barday Z, Manning K, Freercks R, et al. Retrospective Review of ART Regimens in HIV-Positive to HIV-Positive Kidney Transplant Recipients. Kidney Int Rep. 2022. PMID: 36090493. doi:10.1016/j.ekir.2022.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。